India may miss cervical target

Cervical cancer is one of those diseases medicine already knows how to prevent. That is what makes this story frustrating. India has finally started a nationwide HPV vaccination push, but new modelling says the country could still miss the World Health Organization’s elimination path if vaccination, screening, and treatment do not scale much faster. The bigger point is not that the tools are missing. It is that access is uneven — and uneven access can keep a preventable cancer alive for decades. (thelancet.com) ### What changed this week? A new Lancet modelling study sharpened the warning. It argued that, on current trajectories, high-income countries could eliminate cervical cancer around mid-century, while many low- and middle-income countries would keep carrying a much heavier burden far longer. India sits near the center of that problem because its disease burden is already huge and its prevention rollout is only now moving to national scale. (thelancet.com) ### What does “elimination” actually mean? It does not mean zero cases. The WHO definition is getting incidence below 4 cases per 100,000 women. To get there, countries are supposed to hit the “90-70-90” benchmarks by 2030 — 90% of girls vaccinated against HPV by age 15, 70% of women screened with a high-performance test by 35 and again by 45, and 90% of women with precancer or cancer treated. India is not there yet. (who.int) ### Why is India such a hard case? Because the starting burden is so large. India records roughly 127,526 new cervical cancer cases and 79,906 deaths a year, and it accounts for about a quarter of global cervical cancer deaths. That means even a strong new vaccination campaign will not flip the picture overnight. Vaccines protect future cohorts. Screening and treatment are what save women who are already adults and already at risk now. (gavi.org) ### Didn’t India just launch a national HPV campaign? Yes — on February 28, 2026, Prime Minister Narendra Modi launched a nationwide HPV vaccination programme. The first big push aims to provide free shots to about 11.5 million 14-year-old girls through government facilities. That is a major public-health move, and on sheer scale it matters globally. But a launch is not the same thing as coverage. The catch is that elimination depends on actually reaching girls consistently across states, schools, and health systems. (thelancet.com) ### Why won’t vaccination alone solve it? Because cervical cancer has a long timeline. A girl vaccinated at 14 is protected against future HPV-driven disease, but women already in their 30s, 40s, and 50s still need screening and follow-up. That is why cytology, HPV testing, colposcopy, and treatment pathways still matter. In places where screening is patchy, those services are not old infrastructure hanging around by habit — they are the bridge between today’s risk and tomorrow’s prevention. (who.int) ### What does Australia have to do with this? Australia is the useful contrast case. Nationally, it is on track to eliminate cervical cancer by 2035. But new modelling says Aboriginal and Torres Strait Islander women would not reach elimination until 2047 under current conditions. Turns out even a country with strong vaccination and screening can miss equity if underserved groups are not reached. Screening access — including self-collection and culturally safe services — is what closes that gap fastest. (thelancet.com) ### So what is the real lesson? The lesson is that cervical cancer is becoming less a question of scientific capability and more a question of delivery. India now has the vaccine, national political backing, and a clear global target. But unless vaccination, screening, and treatment all move together, the country could still stay far from elimination while richer systems pull away. (thelancet.com) ### Bottom line India’s new HPV rollout is a big step. It is just not the finish line. For the next couple of decades, the countries that beat cervical cancer will be the ones that do both things at once — vaccinate girls for the future, and keep screening and follow-up strong for everyone else now. (thelancet.com)